Atlantic Technology Ventures Appoints New York Investor Relations Firm to Drive Its Next Level of Growth.

Business and Technology Editors

NEW YORK--(BUSINESS WIRE)--April 25, 2001

Atlantic Technology Ventures (NASDAQ: ATLC), a venture company that develops and licenses innovative early stage technologies has appointed The Investor Relations Group, Inc., ("IRG") based in New York as its new financial relations and corporate communications company.

The Investor Relations Group will offer Atlantic Technology Ventures a full complement of investor relations services and will be responsible for heightening investor awareness and helping to lift Atlantic Technologies' profile by individually and personally introducing it to pre-qualified money managers.

In the future, all investor inquiries relating to ATLC should be directed to The Investor Relations Group, New York, N.Y., Telephone: [phone] or Fax: [phone].

"We are expanding our corporate relations program to incorporate a more affirmative outreach into the financial community," said Fred Zotos, President and CEO of Atlantic Technology Ventures. "We are seeking to generate awareness of our publicly traded stock among high-quality, large portfolio funds seeking exciting investment opportunities."

"The Investor Relations Group is a premier investor relations firm that has had a long and impressive track record of success in making introductions and cultivating long-term company relationships with high quality fund managers. We believe The Investor Relations Group will prove to be an excellent choice for the Company," Mr. Zotos said.

About Atlantic Technology Ventures, Inc.

Atlantic Technology Ventures, Inc. is a venture company that focuses on developing and licensing innovative, early stage technologies that address a significant unmet need and offer breakthroughs in performance, efficacy, safety and / or cost effectiveness. With its business model, Atlantic has successfully licensed its proprietary Catarex, a device for cataract removal to Bausch & Lomb (NYSE: BOL), is currently developing CT-3, a synthetic derivative of marijuana for treating pain and inflammation and is also investing in next generation fiber optic communication technologies.

Cautionary statement under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: This press release contains certain forward-looking statements that relate to future scientific, business and financial performance. These statements are only predictions and are subject to a number of risks and uncertainties that may cause the actual events or results to differ from those discussed or implied in these statements. These risks and uncertainties include competition from other manufacturers of related technologies, the unavailability of any necessary intellectual property rights possessed by third parties, and certain of those risks described in Atlantic's most recent report on Form 10-KSB with the Securities and Exchange Commission.